COMPUGEN LEADS CONSORTIUM TO MODEL CANCER RELATED KINASE PATHWAY
Compugen Ltd. has announced that it is leading a consortium for the development
of a platform to simulate the MAP-kinase pathway, a signaling pathway related
to cancer which is already targeted by a number of cancer therapies and diagnostic
tests. The Simulation Modeling of the MAP-kinase Pathway (SIMAP) consortium
is funded by the European Commission which has allocated 3.1 million Euro for
the project over a three year period.